Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

PCI, drugs, medication, fully blocked arteries, chronic total occlusion, ACC.17, clinical study
News | Chronic Total Occlusion (CTO) | March 29, 2017 | Dave Fornell
March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals | March 28, 2017
March 28, 2017 — When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not...
warfarin dosing, genetic testing, adverse event risk, ACC.17, clinical study
News | Antiplatelet and Anticoagulation Therapies | March 27, 2017
March 27, 2017 — Using genetic testing to help personalize warfarin therapy given to patients undergoing elective...
ECRI Institute, top 10 patient safety concerns, 2017 report, information technology, healthcare
News | Information Technology | March 24, 2017
March 24, 2017 — Safe implementation of new technologies and therapies accompany classic patient safety challenges on...
bleeding complications, rivaroxaban, antiplatelet therapy, post-ACS, acute coronary syndrome, ACC.17 study
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017
March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...
rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low dose...
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals | March 22, 2017
March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when...
RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots...
Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals | March 20, 2017
March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology annual...
warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017
March 14, 2017 — More than 80 percent of stroke patients with a history of atrial fibrillation either received not...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra PzF...
ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure | February 22, 2017
February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined...
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies | February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is...
GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals | February 07, 2017
February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma...
electronic health records, EHR, warfarin therapy management, University of Missouri Health Care, blood thinner
News | Antiplatelet and Anticoagulation Therapies | January 17, 2017
January 17, 2017 — Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the...